Home » Lupin Pushes Into Generic Opportunities in the U.S. Pharmaceutical Market

Lupin Pushes Into Generic Opportunities in the U.S. Pharmaceutical Market

February 1, 2013

The U.S. was a key contributor to the overall performance on the back of a strong flu season and the Tricor launch for pharma company Lupin, says Nomura Equity Research.
moneylife

10Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
08Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
15Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval
22Sep
FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

Lupin Pushes Into Generic Opportunities in the U.S. Pharmaceutical Market

Upcoming Events

Gene & Cell Therapy Regulation: Comparability and Other New Developments

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

Hyris T-Cell Test Gains CE-IVD Mark

FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

The Revised ICH E8: A Guide to New Clinical Trial Requirements